Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 8/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 6/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13389777 | 0.89 | ACHE (0.46) | TP53MDM2ACHERAF1MAP2K1 | |
| SCHEMBL3281023 | 0.88 | MDM2 (0.48) | TP53MDM2ACHERAF1MAP2K1 | |
| SCHEMBL13407483 | 0.76 | MDM2 (0.51) | TP53MDM2ACHERAF1KCNH2 | |
| SCHEMBL3280331 | 0.72 | TP53 (0.53) | TP53ACHERAF1MAP2K1SCN5A | |
| SCHEMBL4912856 | 0.68 | MDM2 (1.00) | TP53MDM2KCNH2SCN5ASCN9A | |
| SCHEMBL4912863 | 0.68 | MDM2 (1.00) | TP53MDM2KCNH2SCN5ASCN9A | |
| SCHEMBL4909215 | 0.67 | MDM2 (0.89) | TP53MDM2 | |
| SCHEMBL4909208 | 0.67 | MDM2 (0.89) | TP53MDM2 | |
| SCHEMBL4907057 | 0.66 | MDM2 (1.00) | TP53MDM2 | |
| SCHEMBL4907054 | 0.66 | MDM2 (1.00) | TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705021-B2 | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer | FOX CHASE CANCER CENTER (US) | 2010-04-27 | — | — | US | claimed |
| US-20060264473-A1 | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer | THE INSTITUTE FOR CANCER RESEARCH | 2006-11-23 | — | — | US | claimed |
| US-7705021-B2 | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer | FOX CHASE CANCER CENTER (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060264473-A1 | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer | THE INSTITUTE FOR CANCER RESEARCH | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264473-A1 | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer | CYP27A1, CYP27B1, HSD17B11 | TP53 25/4885MDM2 978/4885ACHE 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.